调整剂量的二肽基肽酶-4 抑制剂用于治疗 2 型糖尿病合并慢性肾脏病患者的经济效益。
Economic benefit of prescribing an adjusted renal dose of dipeptidyl peptidase IV inhibitors in type 2 diabetes patients with chronic kidney disease.
机构信息
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
出版信息
J Diabetes. 2020 Sep;12(9):645-648. doi: 10.1111/1753-0407.13067. Epub 2020 Jun 25.
Highlights Based on nationwide insurance data in Korea, the use of dipeptidyl peptidase IV inhibitors (DPP-IVi) not requiring renal dose adjustment (NRDA DPP-IVi) is widespread in the type 2 diabetes chronic kidney disease (T2D CKD) population. Instead of prescribing NRDA DPP-IVi, the use of DPP-IVi requiring renal dose adjustment with appropriate renal dose adjustments in T2D CKD patients can achieve a considerable annual cost saving of up to 7.8%.
基于韩国全国范围的保险数据，不要求肾剂量调整的二肽基肽酶-4 抑制剂（DPP-4i）在 2 型糖尿病慢性肾脏病（T2D CKD）人群中广泛使用。在 T2D CKD 患者中，不选择使用需要肾剂量调整的 DPP-4i，而是采用合适的肾剂量调整方案，可以节省高达每年 7.8%的可观费用。
Zotero 插件